Statistical Issues of QT Prolongation Assessment Based on Linear Concentration ModelingFootnote∗

∗This article represents the point of views of the authors. It does not necessarily represent the official position of the U.S. FDA.

REFERENCES

• Abernethy , D. R. , Wesche , D. L. , Barbey , J. T. , Ohrt , C. , Mohanty , S. , Pezzullo , J. C. , Schuster , B. G. ( 2000 ). Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation . Br. J. Clin. Pharmacol. 51 : 231 – 237 .
   Google Scholar
• Abernethy , D. R. , Barbey , J. T. , Franc , J. , Brown , K. S. , Feirrera , I. , Ford , N. , Salazar , D. E. ( 2001 ). Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation . Clin. Pharmacol. Ther. 69 : 96 – 103 .
   PubMed Web of Science ®Google Scholar
• Berger , R. L. , Hsu , J. C. ( 1996 ). Bioequivalence trials, intersection-union tests and equivalence confidence interval sets . Statistical Science 11 : 283 – 302 .
   Web of Science ®Google Scholar
• Chen , X. , Cass , J. D. , Bradley , J. A. , Dahm , C. M. , Sun , Z. , Kadyszewski , E. , Engwall , M. J. , Zhou , J. ( 2005 ). QT prolongation and proarrhythmia by moxifloxacin: Concordance of preclinical models in relation to clinical outcome . Br. J. Pharm. 146 : 792 – 799 .
   PubMed Web of Science ®Google Scholar
• Garnett , C. E. , Beasley , N. , Bhattaran , V. A. , Jadhav , P. R. , Madabushi , R. , Stockbridge , N. , Tornee , C. W. , Wang , Y. , Gobburu , J. V. ( 2008 ). Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review . J. Clin. Pharmacol. 48 : 13 – 18 .
   PubMed Web of Science ®Google Scholar
• et al. . ( 1981 ). The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: Concentration-effect relationships . Br. J. Clin. Pharmacol. 11 : 187 – 195 .
   PubMed Web of Science ®Google Scholar
• ICH ( 2005 ). ICH (E14) Guidance. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs. International Conference on Harmonization, May 2005, in Geneva, Switzerland .
   Google Scholar
• Isbister , G. K. , Friberg , L. F. , Duffull , S. B. (2006). Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Intensive Care Med. 32:1060–1065.
   PubMed Web of Science ®Google Scholar
• Malik , M. , Hnatokva , K. , Batchvarov , V. ( 2004a ). Differences between study-specific and subject-specific heart rate correction of QT interval in investigations of drug induced QTc prolongation . PACE 27 : 791 – 800 .
   Google Scholar
• Malik , M. , Hnatokva , K. , Batchvarov , V. , Gang , Y. , Smetana , P. , Camm , J. ( 2004b ). Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation . PACE 27 : 1659 – 1669 .
   Google Scholar
• Piergies , A. A. , Ruo , T. I. , Iansyn , E. M. , Belknap , S. M. , Atkinson , A. I. Ir . ( 1987 ). Effect kinetics of N-acetylprocainamide-induced QT interval prolongation . Clin. Pharmacol. Ther. 42 : 107 – 112 .
   Google Scholar
• Wang , Y. , Pan , G. , Balch , A. ( 2008 ). Bias and variance evaluation of QT interval correction methods . J. Biopharm. Statistics. . (In press).
   Google Scholar
• Zhang , J. , Machado , S. ( 2007 ). Current E14-derived Approach to Design and Statistical Analysis of TQT Studies. ACCP Symposium May 2, 2007, in Baltimore, MD.
   Google Scholar
• ∗This article represents the point of views of the authors. It does not necessarily represent the official position of the U.S. FDA.
   Google Scholar